All posts by: Michael Zand

About Michael Zand

First Patient Treated In Phase II Of Neuralstem ALS Stem Cell Trial – Wall Street Journal

First Patient Treated In Phase II Of Neuralstem ALS Stem Cell TrialWall Street JournalROCKVILLE, Md., Sept. 10, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis … …read more   &nbs… Continue reading

2013-09-10 NEWS

First Patient Treated In Phase II Of Neuralstem ALS Stem Cell Trial – PR Newswire (press release)

First Patient Treated In Phase II Of Neuralstem ALS Stem Cell TrialPR Newswire (press release)10, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s … and … Continue reading

2013-09-10 NEWS